Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab
EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNew […]
EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNew […]
TOKYO, April 22, 2025 /PRNewswire/ — Cosmos Hotel […]
SINGAPORE, April 22, 2025 /PRNewswire/ — Teads, t […]
สิงคโปร์, 22 เมษายน 2568 /PRNewswire/ — Teads แพล […]
New Documentary Explores Hong Kong’s Forgotten Oy […]
SINGAPORE, April 22, 2025 /PRNewswire/ — Banyan G […]
Industry veteran Manish Kalra will help drive growing d […]
JAKARTA, Indonesia, April 22, 2025 /PRNewswire/ — […]
Empowering a new generation, Shahzaib Shah of SSSn is n […]
QUZHOU, China, April 22, 2025 /PRNewswire/ — Agai […]
TAIPEI , April 23, 2025 /PRNewswire/ — Toshiba El […]
OAZisCare, digitally powered by DocquityCare, has advan […]